Our vision: individualize cancer medicine
IR Side Nav
Investor Contact Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Nachricht senden
+49 6131 9084-0
VP Investor Relations & Business Strategy
Nachricht senden
+49 6131 9084-0
Media Contact Jasmina Alatovic
Director Global External Communications
Nachricht senden
+49 89 62 81 75 46
Director Global External Communications
Nachricht senden
+49 89 62 81 75 46
SEC Filings
Filing date | Description | Form | View |
---|---|---|---|
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy |
DRS | View HTML | |
mendment to a previously filed DRS |
DRS/A | View HTML | |
Registration statement for certain foreign private issuers |
F-1 | View HTML | |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A | View HTML | |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A | View HTML | |
Registration of certain classes of securities 12(b) of the Securities Exchange Act |
8-A12B | View HTML | |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A | View HTML | |
EFFECT |
EFFECT | View HTML | |
FWP |
FWP | View HTML | |
Form of prospectus disclosing information facts events covered in both forms 424B1 424B3 |
424B4 | View HTML |
Displaying 1 - 10 of 124 results
Data provided by Kaleidoscope.